Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
作者： Christiane Paatz , Brigitte Moschik , Klaus Korn , Klaus Überla , Martin Helm
DOI:
关键词: Salvage therapy 、 Combination therapy 、 Medicine 、 Oncology 、 Drug 、 Nelfinavir 、 Internal medicine 、 Genotype 、 Immune system 、 Drug resistance 、 Viral load 、 Pharmacology
摘要: In order to analyse whether drug sensitivity testing would be beneficial for clinical decision-making in heavily pretreated patients, we retrospectively studied viral genotype and phenotypic resistance 12 HIV-1-infected each of them with a history failing at least one therapeutic regimen including or two protease inhibitors (PIs). The salvage therapy included nelfinavir as new PI all cases. Four patients showed sustained five transient load decrease. Three failed show significant decline plasma HIV-1 RNA. the baseline samples these cases, against components their combination could detected, whereas antiretroviral was still active cases treatment response. All response harboured viruses that were either fully sensitive resistant only drugs administered. our study, predictive success regimens.
cabdirect.org参考文章(22)
Gerd Fätkenheuer, Richard M.W. Hoetelmans, Nanni Hunn, Achim Schwenk, Caspar Franzen, Marcel Reiser, Alexander Jütte, Jürgen Rockstroh, Volker Diehl, Bernd Salzberger, Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. AIDS. ,vol. 13, pp. 1485- 1489 ,(1999) , 10.1097/00002030-199908200-00007
Steven G. Deeks, Frederick M. Hecht, Melinda Swanson, Tarek Elbeik, Richard Loftus, P. T. Cohen, Robert M. Grant, HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. ,vol. 13, ,(1999) , 10.1097/00002030-199904160-00001
Christophe Piketty, Esther Race, Philippe Castiel, Laurent Belec, Gilles Peytavin, Ali Si-Mohamed, Gustavo Gonzalez-Canali, Laurence Weiss, François Clavel, Michel D. Kazatchkine, Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS. ,vol. 13, ,(1999) , 10.1097/00002030-199907300-00001
Sarah Palmer, Robert W. Shafer, Thomas C. Merigan, Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development AIDS. ,vol. 13, pp. 661- 667 ,(1999) , 10.1097/00002030-199904160-00006
Steven G. Deeks, Nicholas S. Hellmann, Robert M. Grant, Neil T. Parkin, Christos J. Petropoulos, Mark Becker, William Symonds, Margaret Chesney, Paul A. Volberding, Novel Four-Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor-Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic Outcome The Journal of Infectious Diseases. ,vol. 179, pp. 1375- 1381 ,(1999) , 10.1086/314775
Blair Jarvis, Diana Faulds, Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. ,vol. 56, pp. 147- 167 ,(1998) , 10.2165/00003495-199856010-00013
J Durant, P Clevenbergh, P Halfon, P Delgiudice, S Porsin, P Simonet, N Montagne, CAB Boucher, JM Schapiro, P Dellamonica, Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial The Lancet. ,vol. 353, pp. 2195- 2199 ,(1999) , 10.1016/S0140-6736(98)12291-2
A Mocroft, S Vella, TL Benfield, A Chiesi, V Miller, P Gargalianos, A d'Arminio Monforte, I Yust, JN Bruun, AN Phillips, JD Lundgren, Changing patterns of mortality across Europe in patients infected with HIV-1. The Lancet. ,vol. 352, pp. 1725- 1730 ,(1998) , 10.1016/S0140-6736(98)03201-2
Mieke Vandamme, Kristel Van Laethem, Erik De Clercq, Managing Resistance to Anti-HIV Drugs Drugs. ,vol. 57, pp. 337- 361 ,(1999) , 10.2165/00003495-199957030-00006
Hauke Walter, Barbara Schmidt, Klaus Korn, Anne-Mieke Vandamme, Thomas Harrer, Klaus Überla, Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. Journal of Clinical Virology. ,vol. 13, pp. 71- 80 ,(1999) , 10.1016/S1386-6532(99)00010-4